Skip to main content

Alzamend Neuro, Inc.

ALZN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001677077

In the last 90 days, Alzamend Neuro, Inc. insiders filed 1 open-market purchase and 1 sale; 12 institutions reported holding it in 13F filings for Q2 2026, worth $3.26M in total; no superinvestor holds it.

Holders of 5% or more of ALZN

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Alzamend Neuro, Inc., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Alzamend Neuro, Inc. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

6 Schedule 13D and 13G filings on Alzamend Neuro, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on ALZN
Filed (ET)FilerFormStakeChangeEvent dateFiling
Oct 7, 20259:53 PM ETAult Milton C IIIand 8 others13D/A4.40%166.9K shares−3.60 ppfrom 8.00%Below 5%Oct 3, 2025SEC
Oct 3, 20259:37 PM ETAult Milton C IIIand 8 others13D/A8.00%306.3K shares−3.20 ppfrom 11.20%Oct 1, 2025SEC
Sep 30, 20258:51 PM ETAult Milton C IIIand 8 others13D/A11.20%429.7K shares−2.10 ppfrom 13.30%Sep 26, 2025SEC
Sep 25, 20259:37 PM ETAult Milton C IIIand 8 others13D/A13.30%509.3K shares−2.60 ppfrom 15.90%Sep 23, 2025SEC
Sep 23, 20254:30 PM ETAult Milton C IIIand 8 others13D/A15.90%606.3K shares−2.60 ppfrom 18.50%Sep 19, 2025SEC
Aug 1, 20258:52 PM ETAult Milton C IIIand 8 others13D/A18.50%706.3K shares–Jul 23, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Alzamend Neuro, Inc. shares.

No Form 144 notices for Alzamend Neuro, Inc. are on file.